#ASCO21 Among other factors associated with less clinical trial enrollment were age and practice volume. Clinical investigation takes time! Busy practices may not have the ability to enroll as many patients. Administrators take note! Fewer pts in clinic mean more pts on trial.

Flatiron data presented by Dr. Bruno, adding to the pain of our dismal #NGS testing rates, we fail Black patients to an even greater degree in testing and trials. IASLC #ASCO21 #TestALLbiomarkers

So glad that ASCO is highlighting important abstracts such as this one by Dr. Debora Bruno. These differences are real, are harmful, are happening today in front of our eyes. We must do better. #ASCO21 #equity #LCSM

Could not agree more with Dr. Debora Bruno: We need NGS reflex testing for ALL NSCLC.

Exciting to participate in the CHRYSALIS studies Chiles Research Institute Providence Oregon Although higher ORR with EGFR/MET resistance mechanisms identified, the ORR without pathway resistance is not minor. Also, are we to resurrect EGFR IHC given response in EGFR IHC+? #ASCO21 #FinishCancer

Dr. Nowak Anna Nowak giving an excellent summary of the modern state of pleural meso management. 3% response of vin leaves me unenthusiastic. Even IO has only modest gains. We need something better for these patients. IASLC ASCO #ASCO21 #FinishCancer

Intriguing early data @ASCO21 of oncolytic virus therapy for HPV+ tumors, including contributions from Providence Oregon Dr.Rom Leidner. Elegant scientific investigation and signal of immunogenicity. #immunotherapy Chiles Research Institute #FinishCancer

So honored to work Providence Oregon Chiles Research Institute with so many amazing people with the collaborative passion to #FinishCancer

Congratulations, Heather Wakelee ! IASLC is in good hands with your excellent leadership!

Congratulations carlobifulco Providence Oregon Chiles Research Institute . Exemplifies the importance of #TestALLmutations, especially in NSCLC. #LCSM = Knowledge Improves Access to treatment.

#LCSM Chat this Thurs 10/7 5pm PT, 8pm ET: “Best in Show - #LungCancer highlights from #WCLC21 & #ESMO2021 moderated by Charu Aggarwal, MD, MPH, FASCO. IMPORTANT: READ MORE HERE PRIOR TO CHAT: lcsmchat.com/2021/10/04/lcs… Please RT to spread the word! #immunotherapy #targetedtherapy #biomarker

Climate change will increase health disparities. We all need to do our part to help.

This was a fantastic presentation! #WomenInMedicine

Delighted to welcome Dr. Navi Dharampal to our thoracic surgery team. Working primarily out of the Providence Oregon St. Vincent campus, she is expert in robotic surgery & other minimally invasive techniques. Rachel E. Sanborn, MD Regan Duffy, MD, MPH #FinishCancer Providence

So excited to be back in person as the IASLC first Plenary Session kicks off in Vienna. Keep science moving forward! #WCLC22

Watching two fantastic scientists, two fantastic women leaders in the field, and two friends, open the #WCLC2022 IASLC in Vienna

Annabelle Gurwitch, giving a powerful discussion including highlighting the disparities in lung cancer biomarker molecular testing IASLC #WCLC22 Molecular testing for everyone is critical!

Inspiring panel of Women in Thoracic Oncology IASLC #WCLC22 . Very thoughtful discussion of a range of challenges unique to women in the field and in science in general. Times have changed, but there is still so far to go.

New #JITC article: Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors bit.ly/3AayIPM Rachel E. Sanborn, MD Dr. Julie Brahmer

Looking forward to chairing the OncLive.com State of the Science Summit: #LungCancer on Nov 17 at 6pm in Portland! This in-person education event is free to attend. Register at event.onclive.com/event/6d83aa72…. #lcsm Regan Duffy, MD, MPH OncLive SOSS